BMRN Q2 2024 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena

BMRNBioMarin Pharmaceutical Inc.

$12B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$712M+19.6% YoY

Gross Profit

$582M81.7% margin

Operating Income

$120M16.9% margin

Net Income

$107M15.1% margin

EPS (Diluted)

$0.55

QoQ Revenue Growth

+9.7%

Cash Flow

Operating Cash Flow

$119M

Free Cash Flow

$97M

Stock-Based Comp.

$48M

Balance Sheet

Total Assets

$7.1B

Total Liabilities

$1.8B

Stockholders' Equity

$5.3B

Cash & Equivalents

$972M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$712M	$595M	+19.6%
Gross Profit	$582M	$465M	+25.2%
Operating Income	$120M	$66M	+83.7%
Net Income	$107M	$56M	+91.2%

Revenue Segments

Product

$702M99%

Royalty And Other

$10M1%